A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer.

摘要: Metastatic colorectal cancer (mCRC) imposes a substantial health burden on patients and society. In recent years, advances in the treatment of mCRC have mainly resulted from introduction monoclonal antibodies (MoAbs). However, application these MoAbs considerably increases costs. The objective this article is to review assess economic evidence MoAB mCRC. A systematic literature was conducted cost-effectiveness (CE) as well cost-utility-studies were identified. For this, Medline, Embase, SciSearch, Cochrane, nine other databases searched 2000 through February 2013 for full-text publications. quality studies assessed via validated assessment tool (Quality Health Economic Studies (QHES)). total 843 publications screened. Of those, 15 involving bevacizumab, cetux- imab panitumumab met all inclusion criteria. Four analysed CE first-line with bevacizumab cetuximab subsequent lines. Two dealt panitumumab. analysis sequential regimes direct comparison two MoABs by only one study each. included high exception study. Conclusions: consid- ered be not cost-effective testing Kirsten ras onco- gene (KRAS) mutation prior or found clearly compared no testing. Future research should focus upcoming agents like regorafenib aflibercept. Elsevier Ltd. All rights reserved.